Developments Theravance reports new Phase 2 data for ampreloxetine Theravance Biopharma (NASDAQ:TPBH) reported new data from its Phase 2 trial of ampreloxetine in patients with neurogenic orthostatic hypotension (nOH). nOH is characterized by a fall in systolic or diastolic blood... July 22, 2019